Q32 Bio (Q32 Bio) Cash And Cash Equivalents : $115.51 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Cash And Cash Equivalents?

Q32 Bio's quarterly cash and cash equivalents declined from Sep. 2023 ($36.26 Mil) to Dec. 2023 ($25.62 Mil) but then increased from Dec. 2023 ($25.62 Mil) to Mar. 2024 ($115.51 Mil).

Q32 Bio's annual cash and cash equivalents increased from Dec. 2021 ($32.25 Mil) to Dec. 2022 ($43.89 Mil) but then declined from Dec. 2022 ($43.89 Mil) to Dec. 2023 ($25.62 Mil).

Q32 Bio Cash And Cash Equivalents Historical Data

The historical data trend for Q32 Bio's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Cash And Cash Equivalents Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Cash And Cash Equivalents

32.25

43.89

25.62

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial			43.89	-	36.26	25.62	115.51

Q32 Bio Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Q32 Bio (NAS:QTTB) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Q32 Bio Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024